January 2007

Protein That Causes Blood Vessel Leakage in DR Found

CONNI BERGMANN KOURY, EDITOR-IN-CHIEF

Verteporfin and VEGF-Inhibitor Trial for Neovascular AMD

The DENALI trial is the first large-scale, randomized study of verteporfin and ranibizumab.

LEAH FARR, ASSOCIATE EDITOR

Nonselective Followed by Selective VEGF Blockade May Benefit AMD Patients

Combining nonselective and selective VEGF blockade may provide clinical benefit in the treatment of neovascular age-related macular degeneration.

MARK S. HUGHES, MD

Combined PDT With Intravitreal Bevacizumab Useful for Neovascular AMD

Further investigation with large, controlled trials is warranted.

MANDEEP S. DHALLA, MD, AND GAURAV K. SHAH, MD

Ranibizumab Slows Macular Vision Loss

QUAN DONG NGUYEN, MD, MSc, AND PETER A. CAMPOCHIARO, MD

Intravitreal Bevacizumab in Diabetic Macular Edema Improved Visual Acuity, Retinal Thickness

CHRISTOS HARITOGLOU, MD

Intravitreal Bevacizumab Promising for Neovascularization in Diabetic Retinopathy

RODRIGO JORGE, MD, PhD; INGRID U. SCOTT, MD, MPH; AND ROGÉRIO A. COSTA, MD, PhD

The Importance of Vision-Related Quality of Life in Patients Treated for Neovascular AMD

Patients are not interested in telling an E from an F—they want to be able to differentiate a simple building from a work of art.

TOM S. CHANG, MD, FRCS, MHSc

Intravitreal Injections: Technique and Infection Prophylaxis

Although an intravitreal injection is an extremely safe procedure, it is not completely devoid of risk.

MIGUEL BUSQUETS, MD, FACS

Retinal Pigment Epithelium Tears Linked to Bevacizumab?

The investigators suspect a tissue response rather than an injection-related phenomenon.

ULRICH H. M. SPANDAU, MD, AND JOST B. JONAS, MD

Update on Factor H and Genetic Predisposition to AMD: How Geneticists Understand the Disease

There have been major advances in determining what causes AMD— with the main focus on complement factor H.

RANDO ALLIKMETS, PhD

CFH, Hemicentin-1 Genes Not Associated with Dry AMD in Japanese

NOBUO FUSE, MD

Risk Factors and Prevention of AMD

The extent to which a patient experiences morbidity as a result of AMD depends in part on how the tissue responds to complications.

ALBERT O. EDWARDS, MD, PHD

No Association of CFH Gene Polymorphism, AMD in Japanese

JUNKO UKA, MD; HIROKI TAMURA, MD; TAKAYUKI KOBAYASHI, MD; AND ATSUSHI MINAMOTO, MD

Defining the Prevalence of AMD and Investigating Racial Differences

Prevalence rates and racial differences in AMD can help guide the development of screening and treatment policies.

SUSAN B. BRESSLER, MD

Clinical Trial Update: AMD

Trial: Genetic Study of Age-Related Macular Degeneration (AMD)

What are the Legal Issues Regarding the Use of Off-label Drugs?

Jointly sponsored by The Dulaney Foundation and Retina Today Release Date: February 2007. Expiration Date: February 28, 2008. This continuing medical education activity is supported by an educational grant from Genentech.

GEORGE A. WILLIAMS, MD

5 Questions with Debra A. Schaumberg, ScD, OD, MPH

Debra A. Schaumberg, ScD, OD, MPH, is an associate professor at Harvard Medical School, and Director of Ophthalmic Epidemiology at Brigham and Women's Hospital.

Debra A. Schaumberg, ScD, OD, MPH